生物制药公司Nuvation Bio, Inc.（股票代码：NUVB）今日盘中大涨5.13%，引起投资者广泛关注。
根据公司最新发布的2025财年第二季度财报，Nuvation Bio在上半年实现累计收入791.70万美元，较去年同期的143.50万美元大幅增长451.71%。同时，公司净亏损显著收窄，从去年同期的4.77亿美元减少至1.12亿美元，同比缩小76.48%。每股基本亏损也从去年同期的2.06美元改善至0.33美元。
Nuvation Bio成立于2020年，专注于开发创新的肿瘤治疗药物，以解决癌症治疗领域的重大未满足需求。此次财报显示的业绩大幅改善，反映出公司在研发和商业化方面取得了显著进展，这可能是推动股价上涨的主要原因。投资者对公司未来发展前景的信心增强，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.